Swecure is a Swedish biotechnology company developing treatments for immunoregulatory disorders, such as allergy and IBD.
Swecure – immunoregulatory disorders
Swecure AB stands for leading expertise in allergy prevention. The company is working to reduce the prevalence of the most common chronic diseases to improve the quality of life for mankind. Swecure is based on bacteriology and immunology research from Sahlgrenska University Hospital in Sweden with more than 15 years of experience in the area of infant gut bacterial flora. The research group consists of 5 leading researchers with broad experience covering areas such as clinical bacteriology, immunology, rheumatology and gastroenterology. All inventions discovered by this research group are directly transferred to the company for commercialization.
Swecure identifies, develops and markets innovative treatments for allergy prevention as well as autoimmune and inflammatory diseases. The common feature of the products in the pipeline is stimulation of the immune system, together forming a strong product portfolio. Besides developing the first preventive treatment for allergy, Swecure has a number of other products in the works, which will be communicated accordingly. The knowledge and experience of the research team combined with the different business areas is the basis for the development of medical drugs and dietary supplements such as probiotics.
Swecure AB is based in Stockholm (Sweden) and the Research and development department is based in Gothenburg. Management Team is composed by Lars Fahlén and Sofia Östman. Board of directors is composed by Saeid Esmaeilzadeh, Agnes Wold, Alf Lindberg, Jeppe Magnusson, Amin Omrani and Karin Wingstrand.
More about this biotech and biopharma company : www.swecure.com